Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Other Non-Current Assets (2020 - 2025)

Caribou Biosciences has reported Other Non-Current Assets over the past 6 years, most recently at $2.2 million for Q4 2025.

  • Quarterly Other Non-Current Assets fell 60.15% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, down 60.15% year-over-year, with the annual reading at $2.2 million for FY2025, 60.15% down from the prior year.
  • Other Non-Current Assets was $2.2 million for Q4 2025 at Caribou Biosciences, down from $3.8 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $5.5 million in Q4 2024 and troughed at $810000.0 in Q3 2021.
  • The 5-year median for Other Non-Current Assets is $1.6 million (2023), against an average of $2.4 million.
  • Year-over-year, Other Non-Current Assets tumbled 61.63% in 2022 and then skyrocketed 248.11% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $975000.0 in 2021, then soared by 57.74% to $1.5 million in 2022, then grew by 3.12% to $1.6 million in 2023, then skyrocketed by 248.11% to $5.5 million in 2024, then plummeted by 60.15% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Other Non-Current Assets are $2.2 million (Q4 2025), $3.8 million (Q3 2025), and $3.6 million (Q2 2025).